Pfizer’s coronavirus vaccine works very well in children aged 12 to 15, the pharmaceutical giant reported on Wednesday.
In an advanced-stage trial studying more than 2,200 adolescents in the United States, not a single vaccinated person was infected with COVID-19, Pfizer said in a press release. The results suggest that the Pfizer-BioNTech vaccine may be even more effective in 12 to 15 year olds than in adults.
Pfizer has yet to release the test data. The company plans to submit the results to the FDA in the coming weeks, said managing director Albert Bourla, “hoping to start vaccinating this age group before the next school year.”
If it gets emergency clearance, Pfizer’s vaccine will be the first in the United States to be given to children under the age of 16. COVID-19 that the virus is no longer able to spread effectively. President Joe Biden called to vaccinate high school students by the fall in the United States and elementary school students in early 2022, if the results of trials like the one announced by Pfizer show that the vaccines are indeed safe and effective. among them.
Pfizer said the trial showed the vaccine to be safe in young people aged 12 to 15, with side effects “generally consistent with those seen in participants aged 16 to 25.”
Pfizer’s vaccine was first cleared for emergency use in people 16 years of age and older in December, and more than 75 million doses have been given to Americans since then. A clinical trial last fall found it to be 95% effective in reducing COVID-19 infections in adults; a recent study has shown efficacy results that are 90% similar in the “real world” since its authorization.
In the announcement, Pfizer also said it had started vaccinating children ages 5 to 11 in a related global trial and would start giving it to a group of children ages 2 to 2 next week. 5 years.